| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Bicycle Therapeutics plc$4.41
+0.23 (+5.5%)
C 54Pipeline Score Undervalued Pharma · Commercial
Market Cap
299.74 M
EPS
-3.16
P/E Ratio
-1.36 $
Value Trade
1.75 M
SEC Financials
Q1 2026Dilution Risk
Revenue
887.00 K
R&D Expenses
48.90 M
Operating CF
-65.92 M
Total Assets
652.40 M
Total Liabilities
98.08 M
Equity
554.32 M
D/E Ratio
12,345
-1.3 %
Week
-9.54 %
1 Month
-16.67 %
3 Month
-25.77 %
6 Month
-85.18 %
5 Year
-65.97 %
All Time
Cash Data
Cash Position
559.47 M
Monthly Burn
21.98 M
Runway
23.4 mo
Burn Trend
StableSEC Filing
Apr 30, 2026
Overview
Volume
804.20 K
52 Week Range
4.24 - 9.36
% held by Insiders
13.02 %
% held by Institutions
61.81 %
Enterprise Value
-244.34 M
Total Shares
50.27 M
Short %
6.46 %
Float Shares
43.71 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Bicycle Therapeutics plc
262Total events
11Upcoming
59Tier-1 (high impact)
2019 – 2027Coverage
Upcoming catalysts 11
2027
T2Trial Initiation
First company-sponsored radioligand clinical trial for BT1702 expected to initiate
TBD
T2Oral Presentation
Initial dose selection data from Duravelo-2 to be presented at upcoming scientific conference
2026-H1
T2Oral Presentation
Phase 1 BT5528 combination data with nivolumab in mUC patients at a scientific conference
Event history 251
Jun 1, 2026
◆Oral Presentationzelenectide pevedotinPresentation
Interim analysis results from Duravelo-2: zelenectide pevedotin + pembrolizumab in previously untreated la/mUC
previously untreated locally advanced/metastatic urothelial carcinomasource ↗
May 31, 2026
◆Poster Presentationzelenectide pevedotinPresentation
Zelenectide pevedotin plus pembrolizumab in 1L cisplatin-ineligible la/mUC: Update on Duravelo-1 B7
1L cisplatin-ineligible locally advanced/metastatic urothelial carcinomasource ↗
May 29, 2026
◆Oral Presentationzelenectide pevedotinPresentation
Initial dose selection data from Duravelo-2 to be presented at ASCO 2026
metastatic urothelial cancer (mUC)source ↗
Apr 20, 2026
◆Oral Presentationnuzefatide pevedotinPresentation
Update on Nuzefatide Pevedotin and EphA2 Pipeline at AACR 2026
Q2 2026
◆Topline Readoutzelenectide pevedotinClinical Data
Further Duravelo-2 data expected in 2H 2026
metastatic urothelial cancersource ↗
Apr 2026
▲First Patient Dosednuzefatide pevedotinTrial
First patient dosed in Phase 2 trial of nuzefatide in PDAC
recurrent pancreatic ductal adenocarcinoma (PDAC)source ↗
Mar 17, 2026
▼Trial Discontinuedzelenectide pevedotinTrial
Duravelo-4 trial to be discontinued
NECTIN4-amplified non-small cell lung cancersource ↗
Mar 17, 2026
▼Program Discontinuationzelenectide pevedotinCorporate
Zelenectide program deprioritized for internal development
mUCsource ↗
Mar 17, 2026
Mar 17, 2026
▲Partnership / LicenseCorporate
15-year contract with UK Nuclear Decommissioning Authority for RepU access
Drug Pipeline Intelligence
C54
Pipeline Score $1.2B
Pipeline ValueUndervalued
Valuation Signal6
Drugs Scored13.3x
rNPV / MCap Top 82%
Micro Cap (rank 165 of 911)
Percentile RankBicycle Therapeutics plc carries a moderate pipeline score (54/100), with $4.8B risk-adjusted pipeline value, led by BT7480 in Advanced Solid Tumor (Phase 1).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BT7480 Small molecule | Advanced Solid Tumor | Phase 1 | NCT05163041 | 10% | $3.3B | ACTIVE NOT_RECRUITING | 200 | VERY_FAST | C (46) | Dec 1, 2026 | - | LOW May 26, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Bicycle Radioconjugates | various solid tumors | — | 2025-04-29 | 12 patients; SUVmax 6.0 g/mL vs. 10.3 g/mL; SUVmax 4.7 g/mL vs. 4.4 g/mL; SUVmax 7.9 g/mL vs. 6.0 g/mL Read More | Bicycle Therapeutics Announces Presentation of Additional Human Radiopharmaceutical Imaging Data for MT1-MMP at the American Association for Cancer Research Annual Meeting 2025 Data continue to validate the potential of Read More | |
Bicycle Radioconjugates | various solid tumors | — | 2025-04-29 | 12 patients; SUVmax 6.0 g/mL vs. 10.3 g/mL; SUVmax 4.7 g/mL vs. 4.4 g/mL; SUVmax 7.9 g/mL vs. 6.0 g/mL Read More | Bicycle Therapeutics Announces Presentation of Additional Human Radiopharmaceutical Imaging Data for MT1-MMP at the American Association for Cancer Research Annual Meeting 2025 Data continue to validate the potential of Read More | |
Bicycle Radioconjugates | various solid tumors | — | 2025-04-29 | 12 patients; SUVmax 6.0 g/mL vs. 10.3 g/mL; SUVmax 4.7 g/mL vs. 4.4 g/mL; SUVmax 7.9 g/mL vs. 6.0 g/mL Read More | Bicycle Therapeutics Announces Presentation of Additional Human Radiopharmaceutical Imaging Data for MT1-MMP at the American Association for Cancer Research Annual Meeting 2025 Data continue to validate the potential of Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in BCYC
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
BCYC Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
BCYCBicycle Therapeutics to Present Initial Duravelo-2 Data at 2026 ASCO Annual Meeting
Bicycle Therapeutics is set to present initial data from its Duravelo-2 study at the 2026 ASCO Annual Meeting. This presentation is anticipated to provide insights into the efficacy and safety of their therapeutic approach. Details regarding the specific findings or implications of the data have not yet been disclosed.
Read more →BCYCBicycle Therapeutics Reports Recent Business Progress and First Quarter 2026 Financial Results
Bicycle Therapeutics reported its first quarter 2026 financial results, highlighting positive developments in its drug candidates, particularly nuzefatide pevedotin. The company has initiated a Phase 2 trial for nuzefatide in pancreatic cancer and plans to present data at the upcoming ASCO Annual Meeting. Despite a decrease in collaboration revenue and a net loss, Bicycle is focusing on its promising pipeline and maintaining a robust cash position.
Read more →BCYC▼ -6.8%on this news
Bicycle Therapeutics Announces Oral and Poster Presentations at the 2026 ASCO Annual Meeting
Bicycle Therapeutics announced its participation in the 2026 ASCO Annual Meeting, featuring an oral presentation and several poster presentations. The focus is on interim analysis results from studies involving their drug, zelenectide pevedotin, for treating locally advanced and metastatic urothelial carcinoma. The presentations will cover various aspects of the drug's efficacy and dosage optimization.
Read more →BCYCBicycle Therapeutics Provides Update on Nuzefatide Pevedotin and EphA2 Pipeline at the AACR Annual Meeting 2026
Bicycle Therapeutics provided an update on its Nuzefatide Pevedotin and EphA2 pipeline during the AACR Annual Meeting 2026. The details of the update were not disclosed in the article. Further information may be available from the event.
Read more →BCYCBicycle Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2025 Financial Results
Bicycle Therapeutics reported its financial results for Q4 and full year 2025, highlighting the completion of dose selection for the Duravelo-2 trial and the decision to deprioritize the zelenectide program. The company plans to convert the ongoing trial to a randomized Phase 2 study and has initiated a strategic reprioritization of its pipeline, including workforce reductions. Additionally, Bicycle established partnerships to support its radiopharmaceutical pipeline.
Read more →BCYCBicycle Therapeutics Announces Leadership Transitions for Next Phase of Innovation Across Oncology Pipeline
Bicycle Therapeutics has announced key leadership transitions, appointing Travis Thompson as CFO, Michael Method as CMO, and Michael Skynner as CSO. These changes are aimed at advancing the company's oncology pipeline and enhancing its operational capacity. The CEO expressed optimism about the company's financial position and upcoming strategic partnerships in oncology.
Read more →BCYCBicycle Therapeutics Highlights 2025 Accomplishments and Strategic Priorities for 2026 Dose selection from Phase 2/3 Duravelo-2 trial and update on potential approval pathway expected in 1Q 2026 as company seeks feedback
Bicycle Therapeutics has outlined its key accomplishments from 2025 and set strategic priorities for 2026, focusing on the Phase 2/3 Duravelo-2 trial. The company is seeking feedback from regulatory agencies regarding the potential approval pathway for its therapies. Additionally, Bicycle is advancing its radiopharmaceutical pipeline, with new imaging data and updates from ongoing clinical trials expected in the coming year. The financial outlook remains positive, with sufficient runway projected to support these initiatives.
Read more →BCYC▲ +7.1%on this news
Bicycle Therapeutics Reports Recent Business Progress and Third Quarter 2025 Financial Results Dose selection from Phase 2/3 Duravelo-2 trial and update on potential approval pathway expected in 1Q 2026 as company seeks
Bicycle Therapeutics has reported its financial results for Q3 2025, highlighting progress in the clinical development of its innovative drug candidates. The company is seeking regulatory feedback for its drug zelenectide pevedotin in metastatic urothelial cancer while continuing trials for various Nectin-4 associated cancers. Despite a reported net loss of $59.1 million, Bicycle maintains a strong cash position of $648.3 million, ensuring it has a financial runway until 2028. Notable enhancements to its leadership team were also disclosed to bolster innovation and strategic growth.
Read more →BCYCBicycle Therapeutics Strengthens Board of Directors with New Appointments Roger Dansey, M.D., formerly Pfizer and Seagen, and Herv Hoppenot, of Incyte and formerly Novartis Oncology, bring extensive drug development and
Bicycle Therapeutics has appointed Roger Dansey, M.D., and Herv Hoppenot to its Board of Directors, strengthening its leadership in oncology development. Dansey and Hoppenot bring significant experience from their previous roles at Pfizer, Seagen, Incyte, and Novartis. Bicycle is actively advancing its pipeline and anticipates several milestones in the near future. The company focuses on developing innovative therapies based on its proprietary Bicycle technology.
Read more →BCYCBicycle Therapeutics Reports Recent Business Progress and Second Quarter 2025 Financial Results Continued advancement across research and development pipeline, with key program updates expected in 2H 2025 Phase 1/2 Durav
Bicycle Therapeutics has reported its second quarter 2025 financial results, highlighting advancements in its clinical pipeline, particularly with the Phase 1/2 trial for zelenectide pevedotin. The company has strengthened its clinical leadership through new appointments and redefined its strategic direction amid a challenging macroeconomic environment. To optimize operations and extend their financial runway into 2028, Bicycle has announced a workforce reduction, which reflects a proactive approach towards ensuring operational flexibility and prioritizing high-impact programs. Despite recent operational losses, the company retains a solid cash position.
Read more →BCYC▲ +6.1%on this news
Bicycle Therapeutics Reports Recent Business Progress and First Quarter 2025 Financial Results Multiple abstracts accepted for presentation at 2025 ASCO and AACR annual meetings underscore breadth of Bicycle technology a
Bicycle Therapeutics has reported progress in business and financial results for Q1 2025. The company announced multiple abstract acceptances for presentation at the ASCO and AACR annual meetings, highlighting the potential of its oncology pipeline. Additionally, they initiated a Phase 1/2 trial for zelenectide pevedotin in NECTIN4-amplified breast cancer and noted a solid cash position extending their runway into the second half of 2027. Growth in leadership and advisory boards was also mentioned as part of their strategy moving forward.
Read more →BCYCBicycle Therapeutics Announces Presentation of Additional Human Radiopharmaceutical Imaging Data for MT1-MMP at the American Association for Cancer Research Annual Meeting 2025 Data continue to validate the potential of
Bicycle Therapeutics has announced the presentation of additional human imaging data for MT1-MMP at the AACR Annual Meeting 2025, highlighting its potential as a novel cancer target. The data encompass findings from 12 patients with various solid tumors, demonstrating the applicability of Bicycle Radioconjugates (BRC) for radiopharmaceutical imaging. The company plans to initiate clinical trials for its BRCs in 2026 and anticipates initial human imaging data for its second target, EphA2, later this year. The results validate earlier preclinical data and position Bicycle's technology favorably for future cancer therapies.
Read more →BCYC▲ +5.3%on this news
Bicycle Therapeutics Announces New Board and Key Clinical Leadership Appointments Felix J. Baker, Ph.D., to become chairman of Board of Directors Alessandro Riva, M.D., joins Board of Directors and Fabrice Andr , M.D., P
Bicycle Therapeutics has announced significant leadership changes, including Felix J. Baker, Ph.D., as the new chairman of the Board of Directors and the addition of oncology experts Alessandro Riva, M.D., to the Board and Fabrice Andr, M.D., to the Clinical Advisory Board. Eric Westin, M.D., has been promoted to chief medical officer, while Jim MacDonald-Clink has been elevated to senior vice president, head of business development. These appointments follow the planned retirement of several board members and are seen as a step towards strengthening the company's position in oncology drug development.
Read more →BCYCBicycle Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2024 Financial Results Updated topline Phase 1 combination data for zelenectide pevedotin plus pembrolizumab continue to show promisi
Bicycle Therapeutics recently announced its fourth quarter and annual results for 2024, highlighting progress in its pipeline, particularly with zelenectide pevedotin showing promising anti-tumor activity in first-line metastatic urothelial cancer. The company received Fast Track designations from the FDA for treating advanced triple-negative breast cancer and non-small cell lung cancer, further showcasing its potential. Bicycle Therapeutics also plans to initiate multiple Phase 1/2 trials in the coming year and reported a strong cash position expected to facilitate operations into the second half of 2027. Additionally, the company is advancing its radiopharmaceutical development ahead of upcoming trials in 2026.
Read more →BCYC▲ +13.9%on this news
Bicycle Therapeutics Announces Updated Topline Zelenectide Pevedotin Data and Highlights 2025 Strategic Priorities and Milestones Updated topline Phase 1 combination data for zelenectide pevedotin plus pembrolizumab cont
Bicycle Therapeutics announced updated topline results from a Phase 1 trial of its combination therapy, zelenectide pevedotin and pembrolizumab, for treating metastatic urothelial cancer. The data indicates promising anti-tumor activity and a favorable safety profile, reinforcing the therapy's potential as a leading treatment option. The company also outlined its strategic priorities for 2025, including advancements in its emerging pipeline and financial stability through 2027. Bicycle aims to revolutionize treatment for Nectin-4 associated cancers through ongoing trials and new indications.
Read more →BCYCBicycle Therapeutics Announces Data Updates Across Zelenectide Pevedotin Program and Development Strategy Leveraging NECTIN4 Gene Amplification Topline combination data for zelenectide pevedotin plus pembrolizumab in fir
Bicycle Therapeutics has announced positive data updates for its groenectide pevedotin program, particularly showcasing a 60% overall response rate in first-line metastatic urothelial cancer in combination with pembrolizumab. The company plans to advance its development strategy by leveraging NECTIN4 gene amplification, targeting breast cancer, lung cancer, and other tumors in 2025. Notable monotherapy responses were observed in heavily pretreated breast cancer patients, highlighting the potential of zelenectide pevedotin as a new treatment option. Despite ongoing enrollment in the Duravelo-2 trial, the differentiating safety profile and the promising efficacy data position Bicycle Therapeutics favorably in targeted cancer therapies.
Read more →BCYCBicycle Therapeutics Reports Recent Business Progress and Third Quarter 2024 Financial Results Presented updated clinical results across oncology pipeline, including a 45% overall response rate (ORR) for zelenectide peve
Bicycle Therapeutics has reported recent progress and financial results for Q3 2024, highlighting a 45% overall response rate for its oncology products, zelenectide pevedotin and BT5528. The company has also advanced its radiopharmaceuticals pipeline with promising human imaging data. Financially, Bicycle is in a strong position with $890.9 million in cash, although it reported a net loss of $50.8 million, reflecting ongoing operational expenses. The company plans to provide additional updates on its trials and developments by year-end.
Read more →BCYCBicycle Therapeutics Announces First Human Imaging Data from European Association of Nuclear Medicine 2024 Congress and Outlines Strategy for Leadership in Next-Generation Radiopharmaceuticals First human imaging data va
Bicycle Therapeutics announced the presentation of its first human imaging data at the European Association of Nuclear Medicine Congress, highlighting the potential of MT1-MMP as a cancer treatment target. The data showcased the efficacy of Bicycle Radionuclide Conjugates (BRC) in radiopharmaceutical applications, demonstrating optimized biodistribution and significant tumor uptake. Additionally, the company aims to broaden radiopharmaceutical use through strategic collaborations and continued development of its proprietary technology. Bicycle plans to host a conference call to discuss these developments further.
Read more →BCYC▼ -7.6%on this news
Bicycle Therapeutics Presents Updated Clinical Results Across Oncology Pipeline at ESMO Congress 2024 Updated monotherapy data for Nectin-4 targeting zelenectide pevedotin in metastatic urothelial cancer (mUC) showed a p
Bicycle Therapeutics announced updated Phase 1/2 clinical results for its oncology pipeline at the ESMO Congress 2024. Key findings include a 45% overall response rate for the Nectin-4 targeting drug, zelenectide pevedotin, in metastatic urothelial cancer, along with favorable safety profiles for their investigational therapies. The company plans to share more results in the coming months, including combination studies and updates on other therapies targeting various cancers. The development of the company's Bicycle molecules represents a significant step in delivering differentiated treatment options for patients.
Read more →BCYC▲ +7.4%on this news
Bicycle Therapeutics Reports Recent Business Progress and Second Quarter 2024 Financial Results Four abstracts containing data updates across clinical pipeline accepted for poster presentation at ESMO Congress 2024 Focus
Bicycle Therapeutics has reported substantial progress in its business operations and financial results for the second quarter of 2024. The company raised approximately $555 million through a private investment in public equity financing, strengthening its balance sheet significantly. Four abstracts detailing updates on its clinical pipeline were accepted for presentation at the ESMO Congress 2024, showcasing the potential of its therapies. Additionally, Bicycle has streamlined its leadership team and formed a Clinical Advisory Board to further enhance its research and development efforts.
Read more →BCYCBicycle Therapeutics Reports Recent Business Progress and First Quarter 2024 Financial Results Multiple preclinical and clinical abstracts accepted for presentation at 2024 ASCO Annual Meeting and AACR Annual Meeting und
Bicycle Therapeutics has reported promising progress in its business and financial results for Q1 2024. The company has initiated a Phase 2/3 trial for BT8009 targeting metastatic urothelial cancer and anticipates several clinical data updates in the second half of the year. Financially, Bicycle holds $457 million in cash reserves, providing a runway through 2026. Additionally, Mike Hannay has been promoted to Chief Product and Supply Chain Officer, reflecting the company's commitment to internal development and operational excellence.
Read more →BCYCBicycle Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2023 Financial Results Catalyst-rich 2024 with multiple clinical data readouts and updates expected for pipeline and discovery progra
Bicycle Therapeutics has reported its financial results for Q4 and the full year 2023, revealing a solid cash position that extends its financial runway into 2026. The company is actively recruiting patients for its Duravelo-2 trial for BT8009 in metastatic urothelial cancer, with initial data suggesting a positive response. Bicycle's CEO highlighted the company's strategic priorities and upcoming clinical data readouts scheduled for 2024, underlining its unique technology and growth potential. Additionally, the recent appointment of Stephen Sands to the board may provide valuable insights as the company advances its pipeline and discovery efforts.
Read more →BCYC▼ -8.9%on this news
Bicycle Therapeutics Provides Data Updates for Three Clinical Programs and Strategy Overview at First R&D Day Nectin-4 portfolio comprised of BT8009 and BT7480 represents potential opportunity to become leader in treatin
Bicycle Therapeutics has held its first Research & Development Day, providing updates on their clinical programs BT8009, BT7480, and BT5528. The company emphasized its Nectin-4 portfolio, showing promising clinical data in treating metastatic urothelial cancer and other tumor types. Moreover, Bicycle is advancing its EphA2 portfolio, targeting historically undruggable cancer antigens. Steps towards initiating further trials in 2024 indicate a strong pipeline and potential for accelerated approvals.
Read more →BCYCBicycle Therapeutics Reports Recent Business Progress and Third Quarter 2023 Financial Results and Announces Upcoming R&D Day R&D Day on December 14 to provide clinical updates for BT8009, BT5528 and BT7480, and highligh
Bicycle Therapeutics has reported its third quarter 2023 financial results and outlined key business updates. The company has secured alignment with the FDA on an expedited development plan for its investigational therapy BT8009, aimed at metastatic bladder cancer, with clinical trials set to begin in Q1 2024. The company also highlighted its robust financial status, including $572.1 million in cash equivalents. An R&D Day is scheduled for December 14, 2023, to provide further updates on BT8009 and others in the pipeline.
Read more →BCYC▲ +9%on this news
Bicycle Therapeutics Announces Expedited Development Plan for BT8009 in Metastatic Bladder Cancer Alignment with U.S. FDA on design of Phase 2/3 registrational trial, to be initiated in 1Q 2024 Innovative study design al
Bicycle Therapeutics has announced an expedited development plan for its investigational therapy BT8009 in metastatic bladder cancer after aligning with the U.S. FDA on the Phase 2/3 registrational trial design. Named Duravelo-2, the trial is expected to begin in the first quarter of 2024 and includes innovative approaches aimed at potential accelerated approvals for both first-line and previously treated patients. The company aims to assess the efficacy of BT8009 in combination with standards like pembrolizumab, emphasizing their commitment to developing targeted therapies for underserved cancer populations.
Read more →BCYCBicycle Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update Continued progress across pipeline, including advancing BT8009, BT5528, and BT7480 in ongoing clinical trials ; clinical an
Bicycle Therapeutics plc (NASDAQ: BCYC) detailed its second quarter financial results and corporate developments. The company is advancing its clinical pipeline with ongoing trials for BT8009, BT5528, and BT7480, and has secured strategic collaborations with Novartis and Bayer, among others. Financially, it reported a net loss of $42.6 million but noted a strengthened balance sheet, thanks to a public offering in July 2023 and an upfront payment from Bayer. Additionally, the appointment of Alethia Young as the new CFO supports their mission to enhance leadership expertise in the biotech arena.
Read more →BCYCBayer AG Communications 51368 Leverkusen Germany Phone +49 214 30-1 www.bayer.com/en/media News Release Bayer and Bicycle Therapeutics Enter Strategic Collaboration for Development of Novel Targeted Radionuclide Therapie
Bayer AG announced a strategic collaboration with Bicycle Therapeutics to develop novel targeted radionuclide therapies for oncology. This partnership will focus on discovering and commercializing Bicycle radioconjugates, utilizing Bicycle's proprietary bicyclic peptide technology. As part of the agreement, Bicycle will receive a $45 million upfront payment and potential total payments of up to $1.7 billion. The collaboration is aimed at addressing significant unmet medical needs in cancer treatment, although it is subject to regulatory clearance under the U.K. National Security and Investment Act 2021.
Read more →BCYCBicycle Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update - Continued progress across pipeline, including encouraging BT8009 Phase I dose escalation results presented in Q1'23 - Ente
Bicycle Therapeutics reported its financial results for the first quarter of 2023, highlighting positive Phase I results for its investigational drug BT8009, which showed anti-tumor activity in various cancer patients. The company also announced collaborations with Novartis and other organizations to further develop its pipeline of radioconjugates. Financially, Bicycle recorded a net loss of $39.064 million, significantly higher than the previous year, amidst increased operating expenses. The company holds $293.8 million in cash, excluding certain payments from partners, indicating a robust financial position as it advances its clinical programs.
Read more →BCYCBicycle Therapeutics Enhances Leadership Team with Key Appointments - Santiago Arroyo, M.D., Ph.D., appointed Chief Development Officer - Jennifer Perry, Pharm.D., promoted to Senior Vice President, Commercial CAMBRIDGE,
Bicycle Therapeutics has announced key appointments to its leadership team, designating Santiago Arroyo, M.D., Ph.D., as Chief Development Officer and promoting Jennifer Perry, Pharm.D., to Senior Vice President, Commercial. These changes come as the company prepares to move its therapeutics into late-stage clinical development. Dr. Arroyo, with over 20 years of experience in the biopharmaceutical industry, will oversee the expansion of the company's pipeline. The leadership transition aims to strengthen Bicycle's capabilities as it advances its clinical programs in oncology and beyond.
Read more →BCYC▲ +11.1%on this news
Bicycle Therapeutics Announces a Strategic Collaboration with Novartis to Discover, Develop and Commercialize Bicycle Radio-Conjugates - Bicycle and Novartis will collaborate on the discovery and development of multiple
Bicycle Therapeutics has entered into a strategic collaboration with Novartis to develop and commercialize Bicycle radio-conjugates for multiple oncology targets. Novartis will fund all aspects of development and commercialization, with Bicycle receiving a $50 million upfront payment and potential milestone payments of up to $1.7 billion. This partnership aims to leverage Bicycle's innovative technology to advance cancer treatment options, indicating strong validation for the company's approach in the biopharmaceutical sector. The collaboration presents numerous opportunities, along with inherent risks related to dependency on Novartis and the success of product development.
Read more →BCYCBicycle Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update - Significant progress across pipeline including advancing BT8009, BT5528, and BT7480 in ongoing clinical tri
Bicycle Therapeutics reported its financial results for Q4 and full year 2022, highlighting significant progress in its drug pipeline including BT8009, BT5528, and BT7480. The company received Fast Track Designation from the FDA, enhancing its development prospects. As of December 31, 2022, Bicycle maintained a financial position of $339.2 million, which is expected to support its operations through 2025. Despite this, the company reported a notable net loss and substantial operating expenses during the quarter.
Read more →BCYCBicycle Therapeutics Announces Phase I Dose Escalation Results from Ongoing Phase I/II Study of BT8009 50% overall response rate (ORR) and 75% clinical benefit rate, including one complete response in urothelial cancer a
Bicycle Therapeutics announced promising Phase I dose escalation results from its ongoing Phase I/II study of BT8009, a BTC targeting Nectin-4. The study reported a 50% overall response rate and a 75% clinical benefit rate, including one complete response among urothelial cancer patients. Additionally, preliminary efficacy was noted in non-small cell lung cancer and breast cancer patients, suggesting potential broad applicability. The company is advancing with further expansion cohorts and will present the findings at the upcoming ASCO Genitourinary Cancers Symposium.
Read more →BCYC▲ +5.3%on this news· ran to +24% by day 3
Bicycle Therapeutics Announces First Patient Dosed in BT8009 Phase II Expansion Cohorts and Provides Program Update The Phase II multi-center, open label trial will evaluate BT8009 administered at the recommended Phase I
Bicycle Therapeutics Announces First Patient Dosed in BT8009 Phase II Expansion Cohorts and Provides Program Update The Phase II multi-center, open label trial will evaluate BT8009 administered at the recommended Phase II doses of 5mg/m2 and 7.5mg/m2 Phase I dose escalation c
Read more →BCYCBicycle Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Update - Continued clinical progress across pipeline including BT5528 end of Phase I dose escalation update; completion of enrollme
Bicycle Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Update clinical progress across pipeline including BT5528 end of Phase I dose escalation update; completion of enrollment in BT5528 initial dose expansion cohorts expected in Q4 clinical
Read more →BCYCBicycle Therapeutics Announces BT5528 Phase I Dose Escalation Results in Patients with Advanced Solid Tumors Anti-tumor activity observed in heavily pre-treated patients with EphA2-positive ovarian and urothelial cancers
Bicycle Therapeutics Announces BT5528 Phase I Dose Escalation Results in Patients with Advanced Solid Tumors Anti-tumor activity observed in heavily pre-treated patients with EphA2-positive ovarian and urothelial cancers; overall response rates of 22% (including one complete r
Read more →BCYC▲ +11.1%on this news
Bicycle Therapeutics Reports Second Quarter 2022 Financial Results and Provides Corporate Update - Continued clinical progress across pipeline, including dosing of the first patient in expansion cohorts of Phase I/II stu
Bicycle Therapeutics Reports Second Quarter 2022 Financial Results and Provides Corporate Update - Continued clinical progress across pipeline, including dosing of the first patient in expansion cohorts of Phase I/II study of BT5528 - Expansion of Genentech exclusive strate
Read more →BCYCBicycle Therapeutics Announces Further Expansion of Genentech Immuno-Oncology Collaboration Genentech exercises second option to initiate an additional program under the 2020 collaboration agreement CAMBRIDGE, England, &
Bicycle Therapeutics Announces Further Expansion of Genentech Immuno-Oncology Collaboration Genentech exercises second option to initiate an additional program under the 2020 collaboration agreement CAMBRIDGE, England, & BOSTON, July 12, 2022 - Bicycle Therapeutics plc (NASD
Read more →BCYC▼ -5.6%on this news· ran to -23% by day 3
Bicycle Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Update - Continued clinical progress across pipeline, including interim BT8009 Phase I clinical data - Cash and cash equivalents of
Bicycle Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Update clinical progress across pipeline, including interim BT8009 Phase I clinical data and cash equivalents of $407.4 million as of March 31, 2022 expected to provide financial runway t
Read more →BCYC▼ -38.7%on this news· ran to -49% by day 3
Bicycle Therapeutics Announces Interim BT8009 Phase I Clinical Trial Results at the 2022 AACR Annual Meeting - 50% confirmed overall response rate, including one (13%) confirmed complete response in eight urothelial canc
Bicycle Therapeutics Announces Interim BT8009 Phase I Clinical Trial Results at the 2022 AACR Annual Meeting - 50% confirmed overall response rate, including one (13%) confirmed complete response in eight urothelial cancer patients dosed at 5.0mg/m2 weekly Median duration of r
Read more →BCYCBicycle Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update - Continued clinical progress across pipeline of Bicycle Toxin Conjugates (BTCs) and Bicycle tumor-targeted i
Bicycle Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update clinical progress across pipeline of Bicycle Toxin Conjugates (BTCs) and Bicycle tumor-targeted immune cell agonists of $438.7 million at December 31, 2021 expected t
Read more →BCYCBicycle Therapeutics Announces Continued Clinical Progress and Updates to Management Team CAMBRIDGE, England, & BOSTON
Bicycle Therapeutics Announces Continued Clinical Progress and Updates to Management Team CAMBRIDGE, England, & BOSTON, January 5, 2022 - Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its pro
Read more →BCYCBicycle Therapeutics Reports Third Quarter 2021 Financial Results and Provides Corporate Update - Announced interim BT5528 Phase I clinical trial results and preliminary results from ongoing BT8009 Phase I clinical trial
Bicycle Therapeutics Reports Third Quarter 2021 Financial Results and Provides Corporate Update CAMBRIDGE, England, & BOSTON, November 4, 2021 - Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on
Read more →BCYCBicycle Therapeutics Announces Expansion of Genentech Immuno-Oncology Collaboration Genentech exercised an option to initiate an additional program under the 2020 collaboration agreement CAMBRIDGE, England, & BOSTON
Bicycle Therapeutics Announces Expansion of Genentech Immuno-Oncology Collaboration Genentech exercised an option to initiate an additional program under the 2020 collaboration agreement CAMBRIDGE, England, & BOSTON, October 26, 2021 - Bicycle Therapeutics plc (NASDAQ: BCYC)
Read more →BCYC▲ +16.8%on this news· ran to +31% by day 3
Bicycle Therapeutics Announces Interim BT5528 Phase I Clinical Trial Results and Preliminary Results from Ongoing BT8009 Phase I Clinical Trial - BT5528 Phase I anti-tumor activity observed in late line patients, with 2
Bicycle Therapeutics Announces Interim BT5528 Phase I Clinical Trial Results and Preliminary Results from Ongoing BT8009 Phase I Clinical Trial -A recommended BT5528 Phase II dose (RP2D) range has been established at 6.5-8.5mg/m2 every other week; expansion cohorts expected to
Read more →BCYCBicycle Therapeutics Reports Second Quarter 2021 Financial Results and Provides Corporate Update - Entered exclusive license and collaboration agreement with Ionis Pharmaceuticals to develop targeted oligonucleotide ther
Bicycle Therapeutics Reports Second Quarter 2021 Financial Results and Provides Corporate Update CAMBRIDGE, England, & BOSTON, August 5, 2021 - Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on
Read more →BCYCBicycle Therapeutics Enters Exclusive License and Collaboration Agreement with Ionis to Develop Targeted Oligonucleotide Therapeutics - Bicycle to receive a total of $45 million upfront from Ionis and is eligible for dev
Bicycle Therapeutics Enters Exclusive License and Collaboration Agreement with Ionis to Develop Targeted Oligonucleotide Therapeutics - Bicycle to receive a total of $45 million upfront from Ionis and is eligible for development, regulatory and commercial milestone payments
Read more →BCYCBicycle Therapeutics Reports First Quarter 2021 Financial Results and Provides Corporate Update - BT7480, the lead Bicycle tumor-targeted immune cell agonist, presented at AACR Annual Meeting 2021 "New Drugs on the Horiz
Bicycle Therapeutics Reports First Quarter 2021 Financial Results and Provides Corporate Update CAMBRIDGE, England, & BOSTON, May 6, 2021 - Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its
Read more →BCYCBicycle Therapeutics Announces Significant Progress Across Multiple Therapeutic Programs Beyond Oncology - First milestone achieved in neuroscience collaboration with Dementia Discovery Fund and the Alzheimer's Research
Bicycle Therapeutics Announces Significant Progress Across Multiple Therapeutic Programs Beyond Oncology milestone achieved in neuroscience collaboration with Dementia Discovery Fund and the Alzheimer's Research UK Oxford Drug Discovery advances made in the application of Bicy
Read more →BCYCBicycle Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update - Significant progress achieved across pipeline of Bicycle Toxin Conjugates (BTCs ) and tumor targeted immune
Bicycle Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update CAMBRIDGE, England, & BOSTON, March 11, 2021 - Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeu
Read more →BCYCBicycle Therapeutics Announces Pipeline Progress Update - BT1718 progressing in Cancer Research UK sponsored Phase IIa clinical trial - Phase I trial of BT5528 currently dosing within predicted therapeutic range; prelimi
Bicycle Therapeutics Announces Pipeline progressing in Cancer Research UK sponsored Phase IIa clinical trial I trial of BT5528 currently dosing within predicted therapeutic range; preliminary signs of anti-tumor activity observed, including pharmacokinetic profile consistent w
Read more →BCYCBicycle Therapeutics Announces Settlement of Patent Dispute with Pepscan Systems B.V. CAMBRIDGE, England, & BOSTON
Bicycle Therapeutics Announces Settlement of Patent Dispute with Pepscan Systems B.V. CAMBRIDGE, England, & BOSTON - November 20, 2020 - Bicycle Therapeutics plc (NASDAQ:BCYC), a clinical-stage biotechnology company pioneering a new and differentiated class of therapeutics ba
Read more →BCYCBicycle Therapeutics Reports Third Quarter 2020 Financial Results and Provides Corporate Update - Three clinical trials of novel Bicycles initiated this quarter, including a Phase IIa for BT1718, a Phase I for BT8009, an
Bicycle Therapeutics Reports Third Quarter 2020 Financial Results and Provides Corporate Update - Three clinical trials of novel Bicycles initiated this quarter, including a Phase IIa for BT1718, a Phase I for BT8009, and a Phase II for THR-149 - Cash was $149.8 million at Sep
Read more →BCYCExhibt 99.1 Bicycle Therapeutics Announces Gross Proceeds of $50.0 Million from its At-the-Market Offering Program and Enters into Debt Financing from Hercules Capital - ATM offering program initiated during Q3'20 fully
Bicycle Therapeutics Announces Gross Proceeds of $50.0 Million from its At-the-Market Offering Program and Enters into Debt Financing from Hercules Capital -Cash provides runway into 1H'23 through multiple clinical catalysts expected in 2021 CAMBRIDGE, England & BOSTON, Octob
Read more →BCYCBicycle Therapeutics Reports Second Quarter 2020 Financial Results and Provides Corporate Update - Progress across pipeline continues with BT1718 Phase IIa and BT8009 Phase I/II trial initiations on-track for this year -
Bicycle Therapeutics Reports Second Quarter 2020 Financial Results and Provides Corporate Update England, & BOSTON, August 5, 2020 - Bicycle Therapeutics plc (NASDAQ:BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprieta
Read more →BCYCBicycle Therapeutics Reports First Quarter 2020 Financial Results and Provides Corporate Update - Significant recent progress achieved across pipeline of innovative Bicycle - based therapies for oncology and beyond - Dos
Bicycle Therapeutics Reports First Quarter 2020 Financial Results and Provides Corporate Update England, & BOSTON, May 7, 2020 - Bicycle Therapeutics plc (NASDAQ:BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary b
Read more →BCYCBicycle Therapeutics Announces Pipeline Progress Update - Phase I dose escalation completed for BT1718 -RP2D established and preliminary signs of anti-tumor activity observed, including one partial response - Dosing comp
Bicycle Therapeutics Announces Pipeline CAMBRIDGE, England & BOSTON, April 7, 2020 -Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle ) technology, today
Read more →BCYCBicycle Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results and Corporate Updates - BT1718 on track for Phase IIa initiation in 2020; BT5528 Phase I dose escalation is ongoing; BT8009 on track for Ph
Bicycle Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results and Corporate Updates activities for lead TICA BT7480 continue to progress CAMBRIDGE, England, & BOSTON, March 10, 2020 - Bicycle Therapeutics plc (NASDAQ:BCYC), a biotechnology company pioneerin
Read more →BCYCBicycle Therapeutics Announces Exclusive Strategic Collaboration with Genentech to Develop and Commercialize Bicycle - based Immuno-oncology Therapies Bicycle will receive a $30 million upfront payment; upfront payment a
Bicycle Therapeutics Announces Exclusive Strategic Collaboration with Genentech to Develop and Commercialize Bicycle -based Immuno-oncology Therapies Bicycle will receive a $30 million upfront payment; upfront payment and potential discovery, development, regulatory and commer
Read more →BCYCBicycle Therapeutics Reports Third Quarter 2019 Financial Results and Corporate Update - BT7480 selected as lead immuno-oncology candidate to advance into IND-enabling studies - Preclinical data on Bicycle tumor-targeted
Bicycle Therapeutics Reports Third Quarter 2019 Financial Results and Corporate Update - BT7480 selected as lead immuno-oncology candidate to advance into IND-enabling studies - Preclinical data on Bicycle tumor-targeted immune cell agonists to be presented at SITC Annual Meeti
Read more →BCYCConstrained peptides Unconstrained thinking November 2019 Forward-looking statements Nov-2019 2 This presentation may contain forward-looking statements made pursuant to the safe harbor provisions of the Private Securiti
Constrained peptides Unconstrained thinking November 2019 Forward-looking statements Nov-2019 2 This presentation may contain forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements may be i
Read more →BCYCBicycle Therapeutics Announces Presentation of Updated Data from Phase I/IIa Trial Evaluating BT1718 in Patients with Advanced Solid Tumors at ESMO 2019 Annual Congress - Phase I dose escalation continues; dosing is with
Bicycle Therapeutics Announces Presentation of Updated Data from Phase I/IIa Trial Evaluating BT1718 in Patients with Advanced Solid Tumors at ESMO 2019 Annual Congress - Phase I dose escalation continues; dosing is within the therapeutic range predicted by preclinical models -
Read more →BCYCBicycle Therapeutics Reports Second Quarter 2019 Financial Results and Provides Clinical Update - Provides update on the Phase I/IIa trial evaluating lead asset BT1718 in patients with advanced solid tumors - Successfull
Bicycle Therapeutics Reports Second Quarter 2019 Financial Results and Provides Clinical Update - Provides update on the Phase I/IIa trial evaluating lead asset BT1718 in patients with advanced solid tumors - Successfully completed initial public offering (IPO) raising gross pr
Read more →BCYCBicycle Therapeutics Enhances Board of Directors
Bicycle Therapeutics Enhances Board of Directors July 24, 2019 at 8:00 AM EDT Appoints pharmaceutical industry veteran Richard N. Kender, MBA, and life sciences financing professional Janice Bourque, MBA Orderly transition planned for four board members to depart over the next
Read more →Competitive Position
How BCYC ranks across every disease it competes inCompetitive Position is a premium feature
See how BCYC ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial